1 The EIC Accelerator Project
Overview of the EIC Accelerator Program
The EIC Accelerator is a significant funding initiative under the European Innovation Council (EIC) aimed at supporting innovative small and medium-sized enterprises (SMEs) and startups, primarily those engaged in deep tech and breakthrough innovations. This program is designed to facilitate the transition from innovative ideas to market-ready products, enhancing the overall competitiveness of the European economy.
Funding Structure
The EIC Accelerator offers a blended finance model that combines grants and equity investments. The grant component can reach up to €2.5 million, which is intended to support the development and validation of innovative projects. This funding is particularly vital for early-stage companies that may lack the financial resources to bring their innovations to market.
In addition to the grant, the EIC Accelerator provides equity funding, which has undergone some structural changes over the years. Initially, companies could receive equity investments of up to €15 million until 2024, which supports scaling and commercialization efforts. Starting in 2025, this cap is set to decrease to €10 million. This equity component enables companies to attract further private investment while reducing reliance on external funding sources.
Purpose of the EIC Accelerator
The EIC Accelerator plays a pivotal role in the European DeepTech and startup ecosystem by providing financial resources that facilitate the scaling of innovative companies. By bridging the funding gap that often exists in the early stages of technology development, the program allows startups to accelerate their growth trajectories, enhance their market positioning, and attract private sector investments.
The EIC Accelerator not only provides financial support but also offers access to a network of mentors, industry experts, and potential investors. This comprehensive support structure is designed to enhance the likelihood of success for participating companies, fostering an environment conducive to innovation and economic growth.
Case Study: Ligence UAB
Overview of Ligence UAB
Ligence UAB, based in Lithuania, emerged as a winner of the EIC Accelerator program with its innovative project focused on AI-driven cardiac ultrasound analysis. The company submitted its Step 2 proposal on October 6, 2021, and subsequently excelled in the Step 3 interview, securing funding to advance its groundbreaking technology.
Project Description: AI-Driven Cardiac Ultrasound Analysis
The project centers around the development of an advanced AI platform designed to enhance the analysis of cardiac ultrasound imaging. This technology aims to improve diagnostic accuracy and efficiency, which are critical in the early detection and management of various cardiovascular conditions.
Technology Basics and Background
The technology behind Ligence’s AI-driven cardiac ultrasound analysis leverages machine learning algorithms to analyze echocardiographic images. Traditional cardiac ultrasound assessments often rely on manual interpretation by trained cardiologists, a process that can be time-consuming and subject to human error. Ligence’s solution automates this interpretation, streamlining the diagnostic process.
Key features of the technology include:
Overall, Ligence UAB’s project embodies the transformative potential of AI in healthcare, addressing significant challenges in cardiovascular diagnostics. The support from the EIC Accelerator is instrumental in scaling this innovative solution, thereby contributing to the advancement of medical technology and improving healthcare delivery across Europe.
2 The Funding Rounds
Ligence UAB, a Lithuanian startup specializing in AI-powered echocardiography automation technology, has made significant progress in financing and funding since submitting its Step 2 proposal to the EIC Accelerator on October 6, 2021.Financing Raised and Funding Rounds
- In November 2024, Ligence secured a €3 million seed funding round. This round was led by venture capital firm Simpact Ventures and included a convertible loan from the European Innovation Council (EIC) Fund.
- The €3 million financing is intended to fuel Ligence’s expansion efforts as it prepares for FDA clearance anticipated in early 2025. This milestone will enable the company to enter the U.S. market with its echocardiography automation software.
Timing and Amount of Funding
| Date | Type of Funding | Amount | Lead Investor(s) | Notes |
|---|---|---|---|---|
| November 2024 | Seed Round | €3 million | Simpact Ventures; EIC Fund | Convertible loan from EIC Fund included; drives expansion pre-FDA clearance |
The seed round raised at this time appears to be Ligence's most notable external equity financing event reported publicly after their successful EIC Accelerator application.
Investor Information
- The lead investor for this latest funding was Simpact Ventures, a venture capital firm actively investing in deeptech startups.
- The European Innovation Council (EIC) Fund also participated via a convertible loan structure, reflecting ongoing public-private support through EU innovation programs.
Company Valuation and Exit Events
No specific details regarding Ligence’s company valuation or any exit events have been publicly disclosed as of April 2025.
Additional Public Funding Support
Besides private investment rounds:
This blended finance approach combines both non-dilutive grants and equity investments aimed at accelerating product development towards commercialization.
Summary
Since winning the EIC Accelerator award after submitting its Step 2 proposal on October 6th, 2021:
- Ligence UAB has raised approximately €3 million in seed funding led by Simpact Ventures alongside an important convertible loan from the EIC Fund (November 2024).
- It benefits from around €2.5 million grants as part of Horizon Europe’s blended finance program supporting further R&D.
- The funds are primarily dedicated to scaling operations internationally and preparing for FDA clearance targeted for early 2025.
No information is available about company valuations or exits at this stage.
Sources:
https://ligence.io/ligence-attracts-e3-million-investment/
https://www.bebeez.eu/2024/11/13/ligence-raises-e3-million/
https://technews180.com/funding-news/ligence-secures-e3-million-in-seed-funding-investors-include-coinvest-capital/
https://ligence.io/grants/
3 The Press Releases
Ligence UAB: Post-EIC Accelerator Funding Developments Since securing EIC Accelerator funding in October 2021, Lithuania-based Ligence UAB has advanced its AI-driven cardiac ultrasound technology through key partnerships, product enhancements, and expanded clinical integration. Below are highlights from their press releases and updates:Partnerships
- Blackford Collaboration (2023): Ligence partnered with Blackford Analysis to integrate its Ligence Heart AI echocardiography software into Blackford’s imaging platform, enhancing accessibility for healthcare providers globally.
- EIT Ecosystem Support: The company received backing from EIT Climate-KIC, EIT Manufacturing, and EIT Urban Mobility for market expansion and mentorship.
Technology Advancements
- AI-Driven Cardiac Ultrasound: The Ligence Heart web app now offers fully automated transthoracic echocardiogram analysis, generating reports with structural/functional cardiac measurements (e.g., ejection fraction) to support clinical decision-making.
- Workflow Optimization: Recent updates reduced software update distribution times and improved bug resolution efficiency through streamlined developer workflows.
Funding & Growth
- €6M Funding Round (2024): Raised to scale AI solutions for cardiac care, backed by EU grants including the "AI-driven cardiac ultrasound analysis" project co-funded by the European Union.
- Team Expansion: Grew to 24 employees with expertise spanning AI engineering (10+ years), clinical data analysis (70+ combined years of experience), and regulatory compliance.
Regulatory & Security Updates
- CE Mark Compliance: The software meets EU medical device standards with English-language support; translations are available upon request.
- Vulnerability Reporting Protocol: Detailed security issue reporting guidelines were published in August 2024 outlining steps for confidential disclosure and patch deployment.
Key URLs Cited:
Sources: All information derived from Ligence.io announcements and partner disclosures.
4 The Technology Advancements
Ligence UAB, a Lithuanian medical technology company specializing in AI-powered cardiac ultrasound software, has made notable advancements since receiving the EIC Accelerator funding on October 6, 2021.Current Capabilities of Ligence UAB
Ligence develops AI-driven software for cardiac echocardiography that automates image analysis to assist cardiologists in making accurate and rapid clinical decisions. Their platform simplifies diagnostics by providing precise measurements, automated reporting, and a vendor-neutral cardiac viewer that integrates with Picture Archiving and Communication Systems (PACS) or manual DICOM uploads. The software supports English language and can be translated upon customer request. It is CE-marked for sale across the European Union.
The company’s solution aims to improve diagnostic workflow efficiency and accuracy while enabling clinicians to spend more time with patients by reducing manual tasks involved in echocardiogram analysis.
Advancements Since Receiving EIC Accelerator Funding
Since October 2021, Ligence has significantly enhanced its technology:
- Multiple updated versions of their "Ligence Heart" software have been released through 2022 to 2024, reflecting continuous improvements in functionality such as advanced search capabilities, volume measurements (manual stroke volume and automated left ventricle/endocardial border segmentations), user interface enhancements for DICOM handling, annotation features, security updates addressing vulnerabilities responsibly disclosed by users/researchers.
- The company secured an additional €3 million investment round announced in November 2024 led by Simpact Ventures along with other investors including Coinvest Capital and the European Innovation Council (EIC). This investment is directed towards further enhancement of AI algorithms within their platform as well as expansion of ongoing clinical trials across multiple countries including the USA, Germany, Netherlands, Poland, Morocco (testing), Lithuania among others.
Technology Improvements & New Features
The updated releases show incremental but important improvements such as:
- Enhanced measurement techniques providing more reliable quantitative data from echocardiograms.
- Expanded compatibility allowing integration into various hospital IT environments.
- Strengthened data security protocols supporting GDPR compliance.
- Continuous refinement of automated report generation improving workflow automation.
Market Demonstration & Clinical Validation
Ligence’s software is actively used clinically throughout Europe. They are conducting extensive clinical trials internationally — notably in the USA alongside European countries like Germany and Poland — validating their technology's accuracy against experienced cardiologists’ assessments. Testing includes real-world pilot deployments aiming at regulatory approval extensions beyond CE marking which confirms market-level demonstration activity.
Intellectual Property & Publications
While specific recent patent filings or scientific publications directly attributable to Ligence post-EIC funding were not identified from the sources reviewed here:
- The continuous product updates accompanied by detailed instructions for use documents suggest ongoing development possibly supported by proprietary methods embedded within their AI algorithms.
- No explicit mention was found regarding new patents or whitepapers publicly released since October 2021; however clinical trial activities are underway which typically generate scientific data suitable for future publication.
In summary: Since receiving EIC Accelerator funding on October 6th, 2021, Ligence UAB has significantly advanced its AI-based cardiac ultrasound analysis platform through multiple technical updates focused on improved measurement precision and usability enhancements. Their solution is deployed commercially across Europe with active international clinical trials demonstrating validation efforts. A substantial €3 million investment round raised recently further validates investor confidence supporting continued technological innovation at Ligence.
Sources:
[https://ligence.io/wp-content/uploads/2023/10/2.1-IFU-rev.-1.11.pdf]
[https://ligence.io/wp-content/uploads/2024/10/2.1-IFU-rev.-3.38.1-EN_CONS.pdf]
[https://www.vestbee.com/blog/articles/ligence-secures-3-m]
[https://ligence.io/wp-content/uploads/2024/04/2.1-IFU-rev.-3.31.0-EN_CONS.pdf]
[https://www.cobalt.legal/news-cases/a-lithuanian-medical-technology-start-up-ligence-has-secured-a-eur-3-million-investment/]
[https://ligence.io/wp-content/uploads/2024/05/2.1-IFU-rev.-3.32-.0_EN_CONS.pdf]
5 The Partnerships and Customers
Overview of Ligence UAB
Ligence UAB, based in Lithuania, is a company that has gained recognition for its innovative echocardiography software, Ligence Heart. This software is designed to streamline the echocardiography workflow by offering advanced AI-driven analysis and reporting capabilities.
Partnerships and Customers
As of the latest available information, specific names of new partners or customers have not been disclosed publicly. However, Ligence UAB's success has been supported by its involvement in the European innovation ecosystem, notably through the EIC Accelerator funding it received in October 2021. This funding supports the development and scaling of innovative technologies like Ligence Heart.
New Relationships and Market Positioning
The new relationships formed since receiving the EIC Accelerator funding are likely to be strategic, focusing on expanding the company's reach within the healthcare technology sector. While specific partners are not mentioned, the funding and participation in events like RSNA 2023 indicate Ligence UAB's effort to collaborate with key stakeholders in the medical technology industry.
Purpose of New Relationships
These relationships are aimed at enhancing Ligence UAB's position in the market by:
- Advancing Technology: Collaborations will likely focus on further integrating AI and deep learning into echocardiography analysis, potentially leading to more accurate and efficient diagnostic tools.
- Scaling Operations: Partnerships may facilitate the expansion of Ligence Heart's user base and integration with existing healthcare systems (e.g., PACS, EHR).
Impact on Technology Advancements and Scaling
The relationships formed will contribute significantly to Ligence UAB's growth by:
- Enhancing AI Capabilities: Continuous improvement in AI-driven echocardiography analysis will solidify Ligence Heart's position as a leader in medical imaging software.
- Market Expansion: Strategic partnerships can help in entering new markets and increasing the software's adoption rate among healthcare providers.
- Integration with Healthcare Systems: Seamless integration with existing healthcare infrastructure will enhance user experience and encourage broader adoption of Ligence Heart.
Conclusion
Ligence UAB's involvement in the EIC Accelerator program has positioned it favorably for growth and innovation. While specific new partners or customers are not publicly disclosed, the company's strategic approach to partnerships and technology advancements is expected to significantly impact its market presence and contribute to scaling its operations.
Source URLs:
6 The Hiring and Company Growth
Ligence UAB: Team Growth and Hiring
Ligence UAB, a Lithuania-based company focused on applying AI to medical imaging, particularly in cardiovascular diagnostics, has experienced significant growth since receiving the EIC Accelerator funding in October 2021. Here is an overview of their team growth, hiring, and company developments:
Current Headcount and Team Size
Hiring Status
Key Positions Recently Hired
Team Growth
Future Impact of New Team Members
Management and Founding Team Changes
Conclusion
Ligence UAB's strategic hiring and team growth are pivotal in their pursuit of AI-driven innovations in medical imaging. As they expand their team and capabilities, Ligence is well-positioned to make significant impacts in healthcare technology, leveraging their expertise in AI and deep learning algorithms.Source URLs used: - dnb.com
7 The Media Features and Publications
Overview of Ligence UAB
Ligence UAB, an EIC Accelerator winner from Lithuania, received funding in October 2021. The company specializes in developing medical software, particularly the Ligence Heart platform, which is designed for echocardiography analysis. This article will delve into media features, publications, podcasts, conference participations, and event involvement related to Ligence UAB.
Media Features and Publications
Ligence UAB has been featured in various media outlets and publications, though specific details about these publications are not readily available. The company's software has been highlighted in research contexts, such as in the European Heart Journal and European Heart Journal: Cardiovascular Imaging.
Content from Publications
While there are no specific articles detailing Ligence UAB's activities or achievements in major publications, the company is known for its innovative approach to cardiac ultrasound analysis. This includes an ongoing project aimed at increasing the accessibility and quality of heart ultrasound procedures through AI-driven technologies.
Podcasts and Interviews
There is no readily available information on podcasts or interviews conducted by the Ligence UAB team. However, the company's focus on medical innovation suggests potential involvement in industry-specific discussions.
Conference and Fair Visits
Ligence UAB participates in conferences and events within the medical technology sector, though specific details about these participations are not readily available. The company's involvement in such events is crucial for showcasing its echocardiography solutions and engaging with medical professionals.
Event Involvement
Ligence UAB's event involvement includes implementing projects like the "AI-driven cardiac ultrasound analysis," which highlights the company's commitment to advancing medical technology. While there are no specific details on conference presentations or participations, the company's focus on innovation suggests active engagement in relevant medical and technology forums.
In summary, Ligence UAB is a leading developer of echocardiography software solutions, with a strong focus on AI-driven technology. The company has received EIC Accelerator funding, which supports its mission to enhance cardiac ultrasound procedures.
Source URLs:
Do you need EIC Accelerator support?
Here is a list of the key service options for the EIC Accelerator:
Full Writing Service
All proposal sections are written by Stephan Segler, PhD.
Advisory Service
You write in-house but receive 1-on-1 support, templates, instructions, and reviews of all documents.
AI Writer & Training
A high-quality AI writer for EIC Accelerator Step 1 and a comprehensive Training program for Steps 1 and 2 including all templates and instructions.